Dietmar Berger's most recent trade in Gilead Sciences, Inc. was a trade of 533 Restricted Stock Unit done . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2026 | 533 | 46,928 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2026 | 533 | 19,515 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.48 per share. | 10 Jun 2026 | 263 | 19,252 (0%) | 0% | 121.5 | 31,949 | Common Stock |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 31,475 | 31,475 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 8,415 | 47,461 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,133 | 39,046 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,133 | 20,045 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.56 per share. | 10 Mar 2026 | 1,063 | 18,982 (0%) | 0% | 148.6 | 157,919 | Common Stock |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2026 | 8,530 | 17,912 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 16,326 | 16,326 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 16,326 | 41,179 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.60 per share. | 02 Jan 2026 | 6,944 | 9,382 (0%) | 0% | 121.6 | 844,390 | Common Stock |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 37,710 | 37,710 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 8,530 | 57,505 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,975 | 48,975 | - | - | Restricted Stock Unit |